Squamous Cell Carcinoma: From Molecular Mechanisms to Therapeutics
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: closed (20 March 2026) | Viewed by 1078
Editor
Interests: squamous cell carcinoma; skin cancer; melanoma; basal cell carcinoma
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In the era of precision medicine and immune checkpoint inhibitors, head and neck squamous cell carcinoma and non-melanoma skin cancers represent neoplasms that are challenging to treat.
A common way to improve their management is via a multidisciplinary team, but skills in the group must be up-to-date and shared. In locally advanced head and neck cancer, standard treatment has not changed since 2003; recently, chemoradiotherapy plus immunotherapy or xevinapant has failed to change standard chemoradiotherapy practices.
However, some exciting data regarding de-escalation—guided by hypoxia and pathologic risk-based approaches after transoral resections—have been reported. In skin cancer, the use of intra-tumoral approaches for both melanoma and non-melanoma seems very promising. In recurrent metastatic disease, studies are investigating ways to improve immunotherapy outcomes through a combination of different immune checkpoint inhibitors, target and immune checkpoints, or vaccines and immune checkpoints.
Aging and novel techniques guarantee a long life expectancy but also a higher rate of cancer in these frail populations. A deeper knowledge of immune mechanisms and a personalized approach is required.
Dr. Nerina Denaro
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- squamous cell carcinoma
- immunotherapy
- melanoma
- non-melanoma
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
